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Bcl-2Syk is a 72 kDa non-receptor tyrosine kinase that is best characterized in hematopoietic cells. While Syk is
pro-tumorigenic in some cancer cell types, it also has been reported as a negative regulator of metastatic
cell growth in others. An examination of the RelA (p65) subunit of NF-κB expressed in MCF7 breast cancer
cells indicated that either treatment with pervanadate or stable expression of Syk protected RelA from
calpain-mediated proteolysis. Similar results were observed with the tyrosine phosphatase, PTP1B, another
sensitive calpain substrate. The activity of calpain in MCF7 cell lysates was inhibited by both treatment
with hydrogen peroxide and expression of Syk, the former due to oxidative inactivation of calpain and the
latter to enhanced expression of calpastatin (CAST), the endogenous calpain inhibitor. The level of CAST
was elevated in the cytosolic fraction of Syk-positive breast cancer cells resulting in more CAST present
in complex with calpain in cell lysates. The high levels of CAST coincided with elevated basal levels of
calcium–and of intracellular calpain activity–in Syk-expressing cells resulting from decreased levels of
Bcl-2, an inhibitor of IP3-receptor-mediated calcium release. The inhibition of cellular calpain stimulated
the Syk-mediated enhancement of NF-κB induced by TNF-α, enhanced tyrosine phosphorylation resulting
from integrin crosslinking, and increased the localization of Syk to the plasma membrane.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Syk is a 72 kDa protein-tyrosine kinase that is widely distributed
among hematopoietic cells and is found as well in several non-
immune cell types including many epithelial cells [1–5]. Syk can be
activated through the crosslinking of various cell surface receptors in-
cluding those for antigens on lymphocytes, receptors for the Fc regions
of antigen-IgG and -IgE complexes on monocytes, macrophages and
mast cells [1,2], and integrins in both immune and non-immune cells
[6–9]. In B cells, for example, Syk plays a critical role in coupling the an-
tigen receptor (BCR) to downstream pathways that regulate activation,
differentiation andproliferation. Consequently, impaired differentiation
of B-lineage cells is observed in SYK knockout mice [10,11]. The pro-
inﬂammatory cytokine, tumor necrosis factor-α (TNF-α), also is
reported to activate Syk in various cell types including Jurkat T cells
and epithelial cells where the expression of Syk enhances the TNF-
induced activation of NF-κB [12–14].
In cancer cells, Syk has been described as both an enhancer and sup-
pressor of tumorigenesis. The growth and survival of subsets of adultmy-
eloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma,al Chemistry and Molecular
esearch Bldg., 201 S. University
57; fax: +1 765 494 7880.
.
rights reserved.retinoblastoma and pancreatic carcinoma are dependent on Syk [15–20].
In contrast, Syk was identiﬁed as a tumor suppressor in breast cancer
when a correlation between allelic loss of the human SYK locus on chro-
mosome 9q22 and lymph node metastasis of primary breast cancer was
reported [21]. While Syk is expressed in normal human breast epitheli-
um, its level is decreased or lost in highly malignant and invasive breast
cancer cells [3] due to hypermethylation of a CpG-rich fragment in the
5′-regulatory region of the gene [22]. The overexpression of a kinase-
deﬁcient mutant of Syk or the downregulation of Syk expression results
in increased anchorage-independent growth, and motility [3,23]. The
tumor suppressing function of Syk has been attributed to its ability to in-
terrupt normal cell division through its effects onmitosis, its ability to re-
press transcription through interactionswith Sp1 and its ability to inhibit
motility and promote cell–cell interactions [3,24–26].
Cell motility and adhesion also are modulated by the calpain–
calpastatin system, which comprises three molecules: two Ca2+-
dependent proteases, μ-calpain and m-calpain, and calpastatin
(CAST), which is the only known endogenous speciﬁc inhibitor of
calpain. Both μ- and m-calpain are heterodimers comprising an iden-
tical 28-kDa regulatory subunit and a 76–80 kDa catalytic subunit.
The catalytic subunits share 55–65% sequence similarity. CAST has a
large number of isoforms of different molecular weights that are
expressed in a species- and tissue-speciﬁc manner as a result either
of the use of different promoters or alternative splicing of the CAST
gene transcript [27–30].
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for calpain including the cytoskeletal proteins β-catenin, E-cadherin
[31] and β-spectrin [32]; kinases and phosphatases including focal ad-
hesion kinase (FAK) [33], protein kinase C [34], and protein tyrosine
phosphatase 1B (PTP1B) [35,36]; arrestin [37]; and several transcrip-
tion factors including c-Jun, c-Fos [38,39] and p53 [40]. As a result, the
calpain system plays multiple roles under different physiological sce-
narios including, but not limited to, modulation of cell motility, regula-
tion of signal transduction, regulation of gene expression, control of cell
cycle, and regulation of apoptosis. Under normal conditions, the activity
of calpain is tightly regulated by the intracellular concentration of calci-
um, its level of expression, post-translationalmodiﬁcations [41,42], and
the balance between the level of the protease and that of its endogenous
inhibitor CAST [43]. Dysregulation of the calpain system is related to a
wide range of pathologies such asmuscular dystrophies [44], myocardial
infarcts [45], neural degenerative diseases [46], and tumor invasion [47].
Even though limited, documentation in the literature has suggested
some potential for reciprocal regulation between Syk and the calpain
system [48,49]. Given the critical role that calpain plays in cancer metas-
tasis, the potential interactions between Syk and calpain could provide a
better understanding of the tumor promoting and suppressing functions
of Syk in human breast epithelial cells.
2. Materials and methods
2.1. Plasmids and DNA constructs
The series of Syk-expressing constructs (wild type and catalytically
inactive (kinase dead) Syk) with a C-terminal EGFP tag was generated
in the pEGFP-N2 vector (BD Biosciences, CA) as described previously
[50]. The mouse RelA cDNA was cloned into cFLAG-pcDNA backbone
between the HindIII and XhoI restriction sites. A pCMV-SPORT6 plasmid
overexpressing untagged human calpastatin (I.M.A.G.E. Clone ID:
3878564) was purchased from American Type Culture Collection
(ATCC). The calpastatin cDNA was then ampliﬁed by PCR and cloned
into the pCMV-myc vector (BD Biosciences) between the SalI sites to
generate a myc-tagged calpastatin construct (pCMV-myc-CAST). The
NF-κB-driven ﬁreﬂy luciferase reporter pNF-κBluc was obtained from
Stratagene. The internal control plasmid pRL-TK was purchased from
Promega Corporation. The GCaMP3 (plasmid #22692), RelA–FLAG
(plasmid #20012) and FLAG-Bcl-2 (plasmid #18003) expression plas-
mids were obtained from Addgene.
2.2. Cell culture
Three lines of MCF7 cells were used in this study. One was
Syk-deﬁcient, purchased from BD Biosciences (MCF7-BD) [14]; an-
other was positive for endogenous Syk, obtained from American
Type Culture Collection (ATCC) (MCF7-ATCC). The MCF7-Syk cell
line was established by stably reconstituting MCF7-BD cells with
Syk-EGFP. MDA-MB-231 breast cancer cells were obtained from
ATCC. A line of MDA-MB-231 cells expressing Syk-EGFP in response
to tetracycline was described previously [26]. All cell lines were cul-
tured in Dulbecco's modiﬁed Eagle's medium (DMEM) containing
7.5% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin.
2.3. Antibodies and other reagents
Primary antibodies against Syk (N19), Myc (9E10), HA (Y-11),
calpain 4 (capn4) (P-1), and RelA (F-6) were obtained from Santa
Cruz Biotechnology, Inc. Anti-CAST (for Western blotting), anti-
calpain 1 (capn1), and anti-PARP antibodies were from Cell Signaling
Technology. Anti-GAPDH antibody was from Ambion Inc. Anti-
phosphotyrosine antibody (4G10), anti-CAST (for immunostaining),
mouse anti-human CD29 (integrin β1), and protein A-Sepharose
beads covalently conjugated with 4G10 for immunoprecipitationwere purchased from Millipore. Monoclonal anti-FLAG M2 antibody
was purchased from Sigma-Aldrich Corporation. GFP-Trap-A beads
for immunoprecipitation of GFP-fusion proteins were purchased
from ChromoTek. Both goat anti-rabbit and goat anti-mouse horse-
radish peroxidase-conjugated secondary antibodies for Western
blotting were from Thermo Fischer Scientiﬁc Inc. Alexa Flour 594 la-
beled goat anti-mouse IgG for immunostaining was obtained from
Invitrogen Corporation. Calpeptin and staurosporine were purchased
from Sigma-Aldrich Corporation. Calpain 1 puriﬁed from human
erythrocytes and the recombinant CAST peptides were obtained
from Calbiochem. t-Butoxycarbonyl-leucine-methionine-7-amino-4-
chloromethylcoumarin (t-Boc-Leu-Met-CMAC) was purchased from
Invitrogen Corporation. Recombinant human TNF-α was purchased
from R&D Systems. Calpain-Glo Protease Assay and Dual-Luciferase Re-
porter Assay Systems were from Promega Corporation. ProteSEEKER
protease inhibitor kitwas obtained fromG-Biosciences. Rhod-3 imaging
kit was purchased from Invitrogen Corporation.
2.4. Immunoprecipitation
For immunoprecipitation experiments, cells were lysed in buffer
containing 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 1%
NP-40, 1 mM phenylmethylsulfonylﬂuoride (PMSF), 1 mM Na3VO4,
and 0.2% (v/v) protease inhibitor cocktail. Pre-cleared lysate was incu-
batedwith proteinG-Sepharose beads pre-mixedwith primary antibody
and agitated at 4 °C for 4 h. The immune complexes were washed four
times with lysis buffer and resuspended in SDS sample buffer. In some
experiments, cells were treated with sodium orthovanadate (50 μM)
mixed with H2O2 (50 mM) to generate pervanadate (PV), which was
added to the culture medium for a 15 min incubation on ice just before
cells were harvested. Proteins were resolved by SDS-PAGE and detected
by Western blotting using the appropriate primary antibody and horse-
radish peroxidase-conjugated secondary antibody using enzyme-linked
chemiluminescence (ECL) reagents (PerkinElmer).
2.5. Immunoﬂuorescence
Cells seeded on coverslips were ﬁxed in 3.7% formaldehyde, perme-
abilized and blocked in phosphate-buffered saline (PBS) containing
0.5% Triton X-100 and 5% goat serumand stainedwith anti-CAST prima-
ry antibody. Bound antibody was detected with Alexa Fluor® 594 goat
anti-mouse IgG (1:1000). 4′,6′-Diamidino-2-phenylindole (DAPI) was
added for the last 5 min. Slides were examined by an Olympus
BH2-RFCA ﬂuorescence microscope with 60× objective equipped with
a Sony DXC-950 3CCD color camera and Northern Eclipse 5.0 software
from Empix Imaging (Mississauga, Canada).
2.6. Subcellular fractionation
MCF7-BD or MCF7-Syk cells were incubated on ice for 10 min in
buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM dithiothreitol, 0.5 mM PMSF, 1 mM Na3VO4, 0.2% prote-
ase inhibitor cocktail). NP-40 was added to a ﬁnal concentration of
0.2% to lyse cells. Lysates were centrifuged at 18,400 ×g for 30 s.
The supernatant was saved as the cytosol/membrane fraction. The
nuclear pellet was washed twice with buffer A and then resuspended
in 20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, 1 mM PMSF, 1 mM Na3VO4, and 0.2% protease inhibitor
cocktail. The supernatant of a sample centrifuged at 18,400 ×g for
5 min was removed as the nuclear fraction.
2.7. In vitro proteolysis assay of RelA–FLAG
A plasmid encoding FLAG-tagged RelA was transiently transfected
into cells using FuGENE 6 transfection reagent. Cells were lysed as de-
scribed above. In some experiments, whole cell lysates were harvested
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NaCl. Extracts were then reconstituted with lysis buffer containing 1%
NP-40 to dilute the ﬁnal concentration of SDS to 0.1%. Protein
G-Sepharose beads pre-incubated with anti-FLAG (M2) antibody were
used to immunoprecipitate RelA–FLAG. The resulting immune complex
was resuspended in proteolysis buffer (25 mM Tris–HCl, pH 7.5,
10 mM KCl, 10 mM CaCl2, 0.1% Triton X-100) and incubated with 1 μg
puriﬁed human calpain 1 with or without 20 μM recombinant human
CAST peptide at 37 °C for 30 min with gentle shaking. The reaction
was terminated by addition of an equal volume of SDS-sample buffer.
2.8. Dual reporter luciferase assay
MCF7-BD cells were seeded into a 24-well plate (1 × 105 cells/well)
and co-transfected with 0.2 μg/well pNF-κB-Luc reporter plasmid and
0.02 μg/well pRL-TK internal control plasmid, together with indicated
amounts of other expression plasmids. Six hours after transfection,
10 ng/ml recombinant human TNF-α was applied to the cell culture
for an 18 h incubation. Activities of both the ﬁreﬂy luciferase driven
by an NF-κB speciﬁc promoter and the Renilla luciferase control driven
by a TK promoter were measured with a luminometer. The relative lu-
ciferase units (RLU) were calculated as the ratio between the ﬁreﬂy
and Renilla activity readings.
2.9. In vitro calpain protease assay
To measure the activity of calpain in cell lysates, calpain was
immunoprecipitated with a capn 4 antibody from the lysates of MCF7
and MDA-MB-231 cells, treated or not with 50 μM pervanadate. The
resulting immune complex was resuspended in calpain activity assay
buffer (Calbiochem) and incubated with 50 μl calpain-Glo reagent
(Promega Corporation) at room temperature in the dark for 15 min
with or without 5 μM recombinant CAST peptide (Calbiochem). The
luminescence generated from each sample was measured by a
luminometer. Calpain-speciﬁc activity in the lysates was calculated as
the readout difference between samples from the same immune com-
plex, incubated with or without CAST.
2.10. Intracellular calcium imaging
To evaluate qualitatively the calcium level in living cells, a Rhod-3
imaging kit (Invitrogen Corporation) was used. MCF7-BD and
MCF7-Syk cells were seeded onto coverslips in a 6-well plate. Rhod
3-AM (10 μM) was loaded into the cells passively for 30 min in the
dark at room temperature in the presence of 1× PowerLoad concen-
trate and 2.5 mM probenecid. Cells were incubated for 30 min in the
dark at room temperature, washed once with DMEM, ﬁxed in 3.7%
formaldehyde and examined under the ﬂuorescence microscope.
MCF7-BD or MDA-MB-231 cells were transfected with plasmids
encoding the GCaMP3 calcium indicator [51] and FLAG-Bcl-2 as indi-
cated. Cells were placed in a black-walled 96-well plate and assayed
for calcium using a Synergy 4 plate reader and Gen5 software
(BioTek).
2.11. Integrin crosslinking
MCF7 cells were serum starved overnight, collected in Hank's bal-
anced salt solution (HBSS) supplemented with 10 mM EDTA and
washed twice with serum free medium. MCF7 cells in suspension in
serum-free DMEM were incubated with 2.5 μg/ml mouse anti-human
integrin β1 on ice for 30 min, followed by goat anti-mouse secondary
antibody at 37 °C for 15 min. Cells were harvested in 1% NP-40 lysis
buffer and lysates examined by SDS-PAGE and Western blotting with
anti-phosphotyrosine (4G10).2.12. Spreading assay on ﬁbronectin
To prepare ﬁbronectin coated coverslips, 1 ml DMEM containing
20 μg/ml ﬁbronectin was added to each sterilized coverslip placed
in a 6-well plate. The plate was rocked at room temperature for 1 h
and stored at 4 °C overnight. MCF7-Syk cells were pre-treated with
calpeptin (20 μM) or DMSO carrier alone and serum-starved over-
night, removed from the plate using HBSS buffer supplemented
with 10 mM EDTA, and plated on ﬁbronectin-coated coverslips for
1 h at 37 °C. Attached, spread cells were ﬁxed by 3.7% formaldehyde
and examined under the ﬂuorescence microscope.
3. Results
3.1. The expression of Syk inhibits partial proteolysis of RelA in MCF7 cell
lysates
Syk plays an enhancing role in the TNF-α-induced activation of
NF-κB in MCF7 cells [14]. In human umbilical endothelial cells, treat-
ment with TNF-α induces the tyrosine phosphorylation of RelA and
activation of NF-κB [52]. In this system, Syk was reported to interact
directly with endogenous RelA and phosphorylate it on tyrosine
[53]. To investigate a similar interaction between Syk and RelA in
breast epithelial cells, we co-transfected plasmids encoding a
C-terminally EGFP-tagged Syk and a C-terminally FLAG-tagged RelA
into a line of MCF7 cells (MCF7-BD) that lack endogenous Syk. How-
ever, we were unable to detect through co-immunoprecipitation
assays an interaction between Syk-EGFP and either RelA–FLAG or en-
dogenous RelA or the tyrosine phosphorylation of RelA or RelA–FLAG
(Supplementary Fig. S1 and S2).
Western blots of lysates from cells transfected to express RelA–
FLAG revealed, in addition to the 70 kDa full-length RelA–FLAG, two
additional bands, a prominent band migrating at 45 kDa and a
minor band near 60 kDa whose intensities increased with increasing
amounts of RelA–FLAG plasmid. This suggested that RelA–FLAG was
susceptible to proteolysis (Fig. 1A). These two bands were not recog-
nized by an anti-FLAG antibody, indicating that the partial proteolysis
occurred at the C-terminus where the FLAG tag was located. Interest-
ingly, when the expression of Syk (as Syk-EGFP) was restored to the
Syk-deﬁcient cells, the extent of proteolysis of RelA–FLAG was re-
duced signiﬁcantly as compared to the Syk-deﬁcient cells (Fig. 1B).
To determine if the cleavage of RelA–FLAG had occurred prior to or
subsequent to cell lysis, we examined the appearance of the truncated
RelA–FLAG polypeptides in lysates prepared with buffer containing
either 1% NP-40 or 1% SDS. The RelA fragments were dramatically re-
duced in level in cell lysates harvested in lysis buffer containing SDS,
indicating that this partial proteolysis of RelA–FLAG was primarily a
post-lysis event (Fig. 1C).
3.2. RelA is a substrate of calpain
To characterize further the proteolysis of RelA, we treated lysates
of MCF7-BD cells in which RelA–FLAG was overexpressed with a vari-
ety of different protease inhibitors. The production of the 45 kDa
truncated polypeptide was decreased in samples treated with
antipain, chymostatin, E-64, or leupeptin, all of which are inhibitors
of cysteine proteases (Fig. 2A). Proteolysis also was blocked by the ad-
dition of EDTA. These observations indicated the involvement of a
cysteine protease whose activity was dependent on metal ions. This
suggested the possible involvement of calpain, a calcium-dependent
cysteine protease.
To determine if calpain was responsible for the proteolysis of
RelA–FLAG, we added a recombinant peptide inhibitor derived from
human CAST domain I to the lysate of MCF7-BD cells expressing
RelA–FLAG and examined the amount of the truncated RelA polypep-
tide that was formed. The addition of the CAST-derived peptide
Fig. 1. RelA–FLAG is proteolytically processed at its C-terminus in cell lysates. (A) Increasing amounts of RelA–FLAG expression plasmid were transfected into MCF7-BD cells. Cell
lysates (1% NP-40) were resolved by SDS-PAGE, followed by Western blot using antibodies against FLAG and RelA. (B) RelA–FLAG was transiently overexpressed in MCF7-BD
(MCF7) and MCF7-Syk (Syk) cells. Cells were treated or not treated with 50 μM pervanadate (PV) on ice for 15 min. Lysates were analyzed by Western blotting using antibodies
against FLAG, RelA, and Syk. (C) Increasing amounts of RelA–FLAG expression plasmid were transfected into MCF7-BD cells. Cells were harvested in lysis buffer containing either 1%
NP-40 (top panel) or 1% SDS (bottom panel). Cell lysates were analyzed by Western blotting using antibodies against FLAG and RelA. GAPDH served as a protein loading control.
Arrows indicate the major truncated RelA polypeptide.
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when the level of cellular CAST in MCF7-BD cells was elevated by
transient transfection with a full-length CAST expression plasmid,
we observed a signiﬁcant reduction in the generation of the 45 kDa
RelA polypeptide in cell lysates (Fig. 2C). Finally, μ-calpain could read-
ily digest immunoprecipitated RelA–FLAG and this proteolysis was
rescued by the addition of the recombinant CAST peptide (Fig. 2D).Fig. 2. The post-lysis proteolysis of RelA is catalyzed by calpain. (A) Lysates (1% NP-40) from
out (C1) or with different protease inhibitors (1, antipain; 2, aprotinin; 3, bestatin; 4, chym
PMSF; 12, Z-VAD-FMK). Additional controls were lysates of PV-treated cells harvested in s
buffer as the vehicle control for Z-VAD-FMK (C3). Anti-FLAG and RelA antibodies were us
major truncation product of RelA. (B) MCF7-BD cells expressing RelA–FLAG were treated wi
human CAST peptide was included in the lysis buffer used for untreated cells. Lysates were
major truncation product of RelA. (C) MCF7-BD (MCF7) or MCF7-Syk (Syk) cells expressing
transfected with a CAST expression plasmid (TO-CAST). Lysates were Western blotted u
(D) Whole cell lysates (WCL) were collected from MCF7-BD cells expressing RelA–FLAG u
anti-FLAG antibody and incubated at 37 °C for 30 min with either 1 μg puriﬁed calpain 1 alo
mune complexes were resolved by SDS-PAGE and Western blotted using antibodies agains3.3. Inactivation of calpain by hydrogen peroxide
The pre-treatment of cells with pervanadate, a mixture of H2O2
and sodium orthovanadate, abrogated the appearance of the RelA
proteolytic product in cell lysates (Figs. 1B, 2B and C). The sensitivity
of the calpain active site cysteine to oxidation, which inhibits its pro-
teolytic activity [54–56], could explain the loss of protease activity inMCF7-BD cells expressing RelA–FLAG were harvested using buffer supplemented with-
ostatin; 5, E-64; 6, EDTA; 7, leupeptin; 8, pepstatin; 9, AEBSF; 10, phosphoramidon; 11,
tandard lysis buffer (C2) and lysates of DMSO-treated cells harvested in standard lysis
ed for Western blotting. GAPDH served as a loading control. The arrow indicates the
th or without pervanadate (PV) as indicated. Increasing concentrations of recombinant
analyzed by Western blotting using anti-FLAG and anti-RelA. The arrow indicates the
RelA–FLAG were either treated with or without pervanadate (PV) or were transiently
sing antibodies against FLAG, RelA, and CAST. GAPDH served as the loading control.
sing extraction buffer containing 1% SDS. RelA–FLAG was immunoprecipitated using
ne or together with 20 μM recombinant CAST peptide. Both the cell lysate and the im-
t FLAG, and RelA.
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MCF7-BD cells with different concentrations of hydrogen peroxide
and monitored the appearance of truncated CAST migrating as a
70 kDa polypeptide on SDS-polyacrylamide gels as an indicator of
calpain activity in cell lysates since CAST is not only an inhibitor of
calpain, but also an in vitro substrate. The treatment of cells with in-
creasing concentrations of H2O2 decreased the appearance of the
70 kDa CAST fragment in the cell lysates, consistent with oxidative in-
hibition of calpain (Fig. 3A).
It is known that the treatment of cells with H2O2 also inhibits the
activity of protein-tyrosine phosphatases (PTPs) and it has been sug-
gested that calpain is inhibited as a consequence of the inhibition of
PTP activity [57]. The decrease in calpain activity observed in lysates
of cells treated with H2O2 occurred concomitantly with an increase
in protein-tyrosine phosphorylation, which is consistent with an inhi-
bition of PTP activity (Fig. 3A). However, the treatment of cells with a
lower concentration of H2O2 (≤1 mM)was sufﬁcient neither to inhib-
it calpain activity nor to induce extensive protein-tyrosine phosphor-
ylation (Fig. 3B). When a small amount of sodium orthovanadate was
added to the 1 mMH2O2 to generate pervanadate, a mixture of potent
PTP inhibitors, protein tyrosine phosphorylation was elevated, but
calpain activity was not affected (Fig. 3B). Thus, the inhibition of
calpain under oxidizing conditions was independent of the inhibition
of PTP activity. Furthermore, a reduction in overall tyrosine phosphor-
ylation resulting from the addition to cells of the kinase inhibitor
staurosporine failed to restore the calpain activity to lysates of cells
pretreated with pervanadate (Fig. 3C). The addition of puriﬁed
human erythrocyte calpain 1 (μ-capn) plus calcium to the lysate of
pervanadate-pretreated cells restored the appearance of the 45 kDa
truncated RelA polypeptide (Fig. 3D).Fig. 3. Inhibition of calpain activity by hydrogen peroxide. (A) MCF7-BD cells were pretreate
(1% NP-40) were analyzed by Western blotting with antibodies against CAST and phosph
(B) MCF7-BD cells were pretreated with H2O2 (0, 1 or 50 mM) with or without 50 μM Na
CAST and phosphotyrosine (pTyr). (C) MCF7-BD cells pretreated with DMSO (−) or 1 μM s
(1% NP-40) were analyzed by Western blotting with antibodies against CAST and phosp
(D) Lysates from MCF7-BD cells pretreated without (−PV) or with (+PV) pervanadate we
10 ng/μl puriﬁed calpain 1 with or without 10 mM CaCl2. Lysates were analyzed by Western
The arrow indicates the major truncation product of RelA.3.4. Syk and pervanadate decrease calpain activity in immune complexes
Since the expression of Syk or the treatment of cells with
pervanadate (containing a high concentration of hydrogen peroxide)
reduced the partial proteolysis of calpain substrates in cell lysates, we
evaluated the effect of each on the proteolytic activity of calpain using
an exogenous substrate. Endogenous calpain was immunoprecipitated
from lysates of MCF7-BD or MCF7-Syk cells. A luminogenic calpain sub-
strate (Suc-LLVY-aminoluciferin) was used to measure the activity of
the resulting calpain-containing immune complexes. As shown in
Fig. 4A, the expression of Syk resulted in a signiﬁcant reduction in
calpain activity. An even larger decrease in activity was observed in im-
mune complexes isolated from MCF7-BD cells or MDA-MB-231 cells
that had been pretreated with pervanadate (Fig. 4D).
Amajor mode of regulation of calpain, other than the binding of cal-
cium, is the extent of its associationwith its endogenous inhibitor, CAST.
To examine an association between the protease and its inhibitor, we
immunoprecipitated the complex using antibodies against the small
regulatory subunit of calpain, capn4. More CAST was present in the
complex with capn4 in lysates from MCF7-Syk cells as compared to
MCF7-BD cells, consistent with a lower level of protease activity in
these complexes (Fig. 4B and C). CAST associated robustly with capn4
in immune complexes isolated from MCF7-BD or MCF7-Syk cells, but
not from cells that were treated with pervanadate under conditions
that led to the inhibition of calpain (Fig. 4E). The large catalytic subunit
of μ-calpain that was present in the anti-capn4 immune complexes mi-
grated as a single band in both the lysate and in immune complexes
from pervanadate-treated cells, but as a doublet in the immune com-
plexes from control cells. Since a shorter form of the protease is gener-
ated by autolysis, the capn1 doublet observed in the immune complexd with different concentrations of H2O2 or 50 μM PV (containing 50 mM H2O2). Lysates
otyrosine (pTyr). Arrows indicate full-length (FL-CAST) and truncated (CAST*) CAST.
3VO4. Lysates (1% NP-40) were analyzed by Western blotting with antibodies against
taurosporine (STS) were treated on ice for 15 min with pervanadate (PV). Cell lysates
hotyrosine (pTyr). Arrows indicate full-length (FL-CAST) or truncated (CAST*) CAST.
re prepared in lysis buffer containing a recombinant CAST peptide (0, 2, or 10 μM) or
blotting using antibodies against FLAG and RelA. GAPDH served as the loading control.
Fig. 4. Regulation of calpain activity and CAST level by Syk. (A) Calpain was immunoprecipitated from 1% NP-40 lysates of MCF7-BD (MCF7) or MCF7-Syk (Syk) cells with
anti-calpain 4 antibodies and examined for protease activity using the Calpain-Glo protease assay in the presence or absence of 5 μM recombinant human CAST peptide. Levels
of CAST-inhibitable activity are shown in relative light units. The data represent means ± SE (n = 6). (B) Lysates and anti-calpain 4 immune complexes (capn4-IP) from the ex-
periment in panel A were analyzed byWestern blotting with antibodies against Syk, calpain 4 (capn4), μ-calpain (μ-capn) and CAST. (C) The relative level of CAST in the anti-calpain
4 immune complexes was compared between MCF7-BD (MCF7) and MCF7-Syk (Syk) cells. The level of CAST in the complexes from MCF7-BD cells was normalized to a value of 1.0.
The data represent the mean ± SE (n = 3). (D) Calpain was immunoprecipitated from 1% NP-40 lysates of MCF7-BD (MCF7) or MDA-MB-231 (231) cells with anti-calpain 4 an-
tibodies and examined for protease activity using the Calpain-Glo protease assay in the presence or absence of 5 μM recombinant human CAST peptide. Relative levels of
CAST-inhibitable activity are shown. The data represent means ± SE (n = 4). *P b 0.05 when compared to non-treated control; **P b 0.01 when compared to non-treated control.
(E) Calpain was immunoprecipitated with anti-calpain 4 antibodies from 1% NP-40 lysates of MCF7-BD (MCF7) or MCF7-Syk (Syk) cells that were pretreated without or with
pervanadate (PV). Lysates and anti-calpain 4 immune complexes (capn4-IP) were analyzed by Western blotting with antibodies against Syk, CAST, calpain 4 (capn4), μ-calpain
(μ-capn) and CAST.
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tolyzed form. If EDTA/EGTAwas added to cell lysates to chelate calcium,
no CAST was detected in the immune complexes and both the interac-
tions between calpain and CAST or between the large and small sub-
units of calpain were abolished (Fig. S3).
3.5. CAST is more highly expressed in Syk-positive breast cancer cells,
particularly in the cytosolic fraction
To investigate factors that determined thedifference in calpain activity
between lysates of Syk-negative and -positive cells, we examined the rel-
ative expression levels of the protease and its endogenous inhibitor. Anal-
yses by Western blotting revealed no signiﬁcant difference in the
expression level of calpain between MCF7-BD and MCF7-Syk cells. How-
ever, a substantial differencewas observed in the expression level of CAST
with a higher level in theMCF7-Syk cells as compared to the Syk-negative
MCF7-BD cells (Fig. 5A). We also examined the expression of CAST in
MCF7-ATCC, which is a line of MCF7 cells that expresses normal levels
of endogenous Syk [14]. The Syk-positive MCF7-ATCC cells expressed
CAST at a level comparable to MCF7-Syk cells, which was higher than
that observed in MCF7-BD cells. We also examined MDA-MB-231,
which is a highly metastatic breast cancer cell line that lacks any expres-
sion of Syk. These cells expressed the highest level of CAST among the cell
lines examined. Correspondingly, they also exhibited a lower level ofcalpain activity in anti-calpain immune complexes as compared to
MCF7-BD cells (Fig. 4D). These differences in the expression of CAST
were conﬁrmedby immunoﬂuorescence analysis of all four cells using an-
tibodies against the endogenous protein (Fig. 5B). Thus, the level of
calpain activity measured in lysates from cells or in anti-calpain immune
complexes varies between different cell types, but is inversely related to
the level of expression of CAST within the cell.
When measuring the intracellular level of CAST, we also examined
its subcellular distribution through cell fractionation. Cells were divided
into a detergent soluble (cytosol plusmembrane) and a detergent insol-
uble fraction that contained the nuclei. CASTwas found in both fractions
while capn4 was found exclusively in the cytosolic fraction (Fig. 5C).
The two components of the CAST protein doublet that was visible in
Western blots of whole cell lysates were differentially distributed be-
tween the two fractions with the lower, more rapidly migrating band
present only in the cytosolic fraction and the upper bandpredominantly
in the nuclear fraction. The increased amount of CAST that was present
in cells expressing Syk was in the soluble fraction.
3.6. Intracellular calcium levels are high and Bcl-2 levels low in
Syk-expressing cells
Since cells expressing higher levels of CAST exhibited lower levels of
calpain activity in lysates or immune complexes, we asked whether or
Fig. 5. Expression of CAST in breast cancer cell lines. (A) Lysates (1% NP-40) of MCF7-BD (7), MCF7-Syk (Syk), MCF7-ATCC7 (A7), and MDA-MB-231 (231) cells were analyzed by
Western blotting using an anti-CAST antibody. GAPDHwas detected as a loading control. The expression level of endogenous CAST was normalized to that of GAPDH. Data represent
means ± SE (n = 3 for each measurement). (B) Endogenous CAST in MCF7-BD (MCF7), MCF7-Syk (Syk), MCF7-ATCC (ATTC7), andMDA-MB-231 (231) cells was detected using an
anti-CAST antibody and a ﬂuorescently tagged secondary antibody. DAPI was used to stain the nuclei. (C) Cytosolic (C) and nuclear (N) fractions of MCF7-BD cells untreated (MCF7)
or pretreated (7 + PV) with pervanadate (PV) and MCF7-Syk cells (Syk) were analyzed by Western blotting using antibodies against CAST, calpain 4 (capn4) and GAPDH. The in-
tensity of the upper CAST band in the cytosolic fraction was normalized to that of the nuclear CAST band to indicate the fold increase in the cytosolic amount of the slower-migrating
CAST polypeptide.
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tent. For this assay, we used a cell permeable calpain substrate (t-Boc-
Leu-Met-CMAC) whose cleavage can be detected by ﬂuorescence mi-
croscopy. The treatment of cells with increasing concentrations of
calpeptin, a calpain inhibitor, led to a decrease in ﬂuorescence intensity
as did the treatment of cells with pervanadate, conﬁrming the depen-
dency of the assay on calpain activity (Fig. 6A and B). Surprisingly, a
5-fold increase in ﬂuorescence intensity was observed in MCF7-Syk
cells as compared to Syk-negative MCF7-BD cells despite the higher
levels of endogenous CAST (Fig. 6C). Since calcium is the most impor-
tant regulator of calpain activity, we compared the relative levels of in-
tracellular calcium in the Syk-deﬁcient MCF7-BD and Syk-expressing
MCF7-Syk cells. An examination of cells passively loaded with Rhod-3
revealed an approximately 4-fold increase in ﬂuorescence in the
MCF7-Syk cells as compared to Syk-deﬁcient MCF7-BD cells, indicating
that the level of calcium in the Syk-expressing cells was higher than in
Syk-deﬁcient MCF7 cells (Fig. 6D). This observation provides an expla-
nation for the higher calpain activity within live MCF7-Syk cells despite
the higher level of CAST.
The level of free intracellular calcium is, in part, a product of its release
from intracellular stores in the endoplasmic reticulum. The release of cal-
cium ismediated by IP3 receptors,which are, in turn, negatively regulatedby the anti-apoptotic protein, Bcl-2 [58,59]. To determine if Bcl-2 might
contribute to the differences in intracellular calcium observed between
the Syk-deﬁcient versus Syk-positive cells, we examined the relative
levels of the protein in the two cell types. Interestingly, the level of Bcl-2
was much higher in the Syk-deﬁcient MCF7-BD than in the MCF7-Syk
cells (Fig. 6E). A similar difference in expression was observed between
the MCF7-BD cells and the MCF7-ATCC cells that express endogenous
Syk. To verify a role for Bcl-2 in the regulation of intracellular calcium in
breast cancer cells, we transfected MCF7-BD cells with a plasmid coding
for the calcium-indicator protein GCaMP3 along with an expression plas-
mid for FLAG-tagged Bcl-2 or an empty vector. The expression of
FLAG-Bcl-2 resulted in a substantial decrease in the intracellular concen-
tration of calcium, consistent with an inhibitory role for Bcl-2 in calcium
release from the ER in MCF7 cells (Fig. 6F).
Since the level of CAST also was higher in MDA-MB-231 than in
MCF7-BD cells, we predicted that the level of Bcl-2 would be low in
these cells, similar to what was observed for MCF7-Syk cells. Indeed,
Western blotting analyses of cell lysates revealed a much lower level of
Bcl-2 in MDA-MB-231 cells as compared to MCF7-BD cells (Fig. 6E). The
expression of exogenous Bcl-2 in these cells again dramatically lowered
the level of intracellular calcium as measured by GCaMP3 ﬂuorescence
(Fig. 6G).
Fig. 6. Elevated levels of calpain and calcium in Syk-expressing cells. (A) MCF7-BD cells pretreated with increasing concentrations of calpeptin were incubated with 10 μM
BOC-Leu-Met-CMAC at 37 °C for 1 h before ﬁxation and examination by ﬂuorescence microscopy. (B) MCF7-BD cells were either pretreated or not with 50 μM PV and then with
50 μM BOC-Leu-Met-CMAC at 37 °C for 15 min. Fixed cells were then examined under the ﬂuorescence microscope. (C) MCF7-BD (MCF7) and MCF7-Syk (Syk) cells were incubated
with 10 μM BOC-Leu-Met-CMAC at 37 °C for 1 h, ﬁxed and examined by ﬂuorescence microscopy. (D) MCF7-BD (MCF7) and MCF7-Syk (Syk) cells loaded with Rhod-3AM were
ﬁxed and examined by ﬂuorescence microscopy. (E) Lysates from MCF7-BD (MCF7), MCF7-Syk (Syk) MCF7-ATCC (A7) and MDA-MB-231 cells were analyzed by Western blotting
with antibodies against Bcl-2, GAPDH and Syk. (F) MCF7-BD cells were transfected with the GCaMP3 expression plasmid along with either an empty vector (−) or FLAG-Bcl-2
expression plasmid. Lysates were analyzed by Western blotting using antibodies against Bcl-2 and GAPDH. Fluorescence was measured with a plate reader. Values represent the
means ± SE (n = 3). (G) MDA-MB-231 cells were analyzed as described in panel F.
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Based on the observed connections between Syk and the calpain
system, we asked how the inhibition of calpain might affect known
Syk-regulated pathways in epithelial cells. Since the re-expression of
Syk in MCF7-BD cells enhances the TNF-α-induced activation of NF-κB
[14], we asked if calpain might be involved in this regulation. MCF7-
BD cells were transiently transfected with an expression plasmid for
either EGFP or Syk-EGFP, an NF-κB-driven luciferase reporter plasmid,
a TK-luciferase internal control plasmid, and either a plasmid encodingFig. 7. Effect of calpain on TNF-α and integrin signaling. (A) MCF7-BD cells were transfecte
expression plasmids for Syk-EGFP (Syk) and/or myc-CAST (CAST) (0.1 or 0.3 μg). Cells were
Lysates were analyzed byWestern blotting with anti-Syk and anti-myc epitope antibodies. D
experiments performed in triplicate. *P b 0.05; ***P b 0.001. (B) Lysates (1% NP-40) of MCF
were analyzed by Western blotting with antibodies against PTP1B, Syk and GAPDH. (C) Lys
with calpeptin were analyzed by Western blotting with antibodies against PTP1B. Arrows
MCF7-BD (MCF7) or MCF7-Syk (Syk) cells pre-treated with or without calpeptin and then
an antibody against phosphotyrosine (pTyr). (E) MCF7-Syk cells were pretreated with 20 μ
on ﬁbronectin (2 μg/ml) coated coverslips at room temperature for 1 h. Cells were ﬁxed a
cell edge was normalized to that in the cytosol and plotted as a histogram. Data represe
DMSO control. (F) PTP1B was immunoprecipitated from lysates of MDA-MB-231 cells lack
promoter and pre-treated with or without pervanadate (PV). Lysates and immune complexCAST or an empty vector. The expression of Syk-EGFP or CAST alone en-
hanced the TNF-α-induced activation of NF-κB while a combination of
CAST and Syk resulted in a substantial increase in activation (Fig. 7A).
This suggests that, by inhibiting calpain activity, CAST plays a positive
role in TNF-α-induced NF-κB activation in MCF7 cells.
3.8. PTP1B is a substrate of calpain
In addition to RelA, a number of other cellular proteins have been
described that are uniquely sensitive to calpain-mediated cleavage.d with the control and NF-κB-luciferase reporter plasmids and either empty vectors or
stimulated with 10 ng/ml TNF-α at 37 °C for 18 h and assayed for luciferase expression.
ata are normalized to vector only controls and represent the ±SE of three independent
7-BD (MCF7) and MCF7-Syk (Syk) cells pretreated without or with pervanadate (PV)
ates (1% NP-40) of MCF7-BD (MCF7) and MCF7-Syk (Syk) cells pretreated without or
indicate migration positions of full-length (FL) and cleaved PTP1B. (D) Lysates from
treated in suspension with anti-β1-integrin were analyzed by Western blotting using
M calpeptin or DMSO for 24 h were detached from plates and then allowed to spread
nd examined under the ﬂuorescence microscope. The distribution of Syk-EGFP at the
nt means ± SE (n = 30 for each measurement). *P b 0.0001 when compared to the
ing Syk (TR) or induced to express Syk-EGFP (TRS) under control of a Tet-responsive
es were analyzed by Western blotting with antibodies against PTP1B and Syk.
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mine if PTP1B was susceptible to proteolysis by calpain in breast epi-
thelial cells, we compared lysates from cells either expressing or
lacking Syk. MCF7-BD and MCF7-Syk cells were pretreated without
or with pervanadate under conditions where it inhibited calpain ac-
tivity. As shown in Fig. 7B, the cleavage of PTP1B to generate the
smaller, more rapidly migrating form was readily observed in lysates
from Syk-deﬁcient cells. This cleavage again was reduced in lysates
from cells expressing the kinase and in lysates of cells treated with
pervanadate and was blocked by calpain (Fig. 7C). Thus, PTP1B, like
RelA, was sensitive to calpain-mediated cleavage in cell lysates and
the stable expression of Syk in MCF7 cells partially inhibited its cleav-
age due to increased CAST expression.
In epithelial cells, the cross-linking of integrins leads to the activa-
tion of Syk [12,26]. Interestingly, integrin engagement in both platelets
and breast cancer cells also results in the cleavage of PTP1B to generate
the smaller, catalytically more active fragment [35,36,60]. To begin to
investigate the effect of calpain on Syk-mediated integrin signaling,
the cellular level of tyrosine phosphorylation was monitored in
MCF7-BD and MCF7-Syk cells following integrin crosslinking in the
presence or absence of the cell permeable calpain inhibitor calpeptin.
The integrin-stimulated phosphorylation of proteins on tyrosine was
enhanced by the addition of calpeptin in the Syk-expressing cells
(Fig. 7D). In human umbilical vein endothelial cells (HUVEC), more
Syk was observed in the membrane fraction following the inhibition
of calpain [48]. To investigate the inﬂuence of calpain inhibition on
the intracellular localization of Syk in MCF7-Syk cells, we pretreated
MCF7-Syk cells with calpeptin for 24 h and then plated these on
ﬁbronectin-coated coverslips. After 1 h, cells were ﬁxed and the locali-
zation of Syk-EGFP was examined under the ﬂuorescence microscope.
Consistent with our previous observations, Syk was found to be
expressed in both the cytosol and the nucleus [26]. When calpain was
inhibited by calpeptin, a 4-fold increase in the amount of Syk present
at the edge of spreading cells was observed as compared to the control,
DMSO-treated cells (Fig. 7E). To determine if Syk and PTP1B might be
directly or indirectly associated with one another, we immuno-
precipitated PTP1B from a line of MDA-MB-231 cells in which the ex-
pression of Syk (as Syk-EGFP) could be induced by tetracycline.
Indeed, Syk-EGFP could be readily visualized by Western blotting in
anti-PTP1B immune complexes isolated from lysates of cells induced
to express the kinase (Fig. 7F).
4. Discussion
In hematopoietic cells, Syk plays a pivotal role in coupling a variety
of different membrane-associated receptors to diverse intracellular sig-
naling pathways, leading to enhanced proliferation and differentiation.
It also plays a pro-survival role in a variety of malignancies [15–17,19].
In MCF7 human breast adenocarcinoma cells, Syk enhances the
TNF-α-induced activation of NF-κB and protects cells from apoptosis
[14]. To investigate how Syk enhances TNF-α-induced NF-κB activation,
we explored a potential interaction between Syk and RelA, a subunit of
NF-κB. Although neither an interaction with Syk nor the tyrosine phos-
phorylation of RelA could be detected, we did ﬁnd that overexpressed
RelA is partially proteolyzed in lysates of MCF7 cells and that the stable
expression of Syk decreases this proteolysis. In a series of experiments
using a variety of different protease inhibitors, we ﬁnd that the proteol-
ysis of RelA is catalyzed by calpain, awidely expressed cysteine protease
that is tightly regulated by calcium.
The identiﬁcation of calpain as the responsible protease also was
supported by its sensitivity to inactivation through oxidation. The
pre-treatment of cells with pervanadate inhibited the subsequent re-
covery of active calpain in cell lysates. This effect required high concen-
trations of H2O2 and was independent of the pervanadate-induced
inhibition of PTP activity, suggesting an inhibitorymechanism involving
direct oxidative modiﬁcation of the cysteine-containing catalytic triad.This is consistent with previous reports that calpain can be inhibited
by H2O2-triggered oxidative stress both in vitro and in vivo [54,55]. An
analysis of H2O2-oxidized μ-calpain puriﬁed from porcine skeletal mus-
cle bymass spectrometry revealed an intramolecular disulﬁde bond be-
tween the active site cysteine (Cys115) and Cys108 [56].
The different levels of calpain activity present in MCF7 cell lysates
are dictated by the level of expression in the cell of its inhibitor, CAST;
and the expression level of CAST is affected by the presence or ab-
sence of Syk in the cells. Conventional MCF7 cells (MCF7-ATCC) that
express normal levels of the kinase express higher levels of CAST
than do Syk-deﬁcient MCF7-BD cells. However, the amount of CAST
in the MCF7-BD cells is restored to near normal levels by the
re-expression of the kinase. No obvious change in calpain expression
is observed between Syk-negative and -positive cells. CAST levels are
also higher in MDA-MB-231 cells than in MCF7-BD cells even though
these cells lack endogenous Syk. However, these cells do express the
EGF receptor tyrosine kinase at high levels, which could possibly be
coupled to the enhanced expression of CAST if this is a tyrosine
kinase-regulated event. In all cases, the level of calpain activity in
cell lysates and in immune complexes is inversely related to the
level of CAST expressed in the cell and likely, therefore, reﬂects the
formation of inactive calpain-CAST complexes once cells are lysed.
The increased amount of CAST found in the Syk-expressing cells
was present primarily in the soluble fraction of the cell. Although
encoded by a single gene, CAST is expressed as multiple isoforms
due to alternative splicing events that most frequently result in the
elimination of regions encoded by exon 3 or exons 3 and 5. As consis-
tently observed by Western blotting, the endogenous CAST protein in
breast cancer cells migrates on SDS-PAGE as multiple bands, consis-
tent with the presence of more than a single isoform. The more rapid-
ly migrating forms are present in the soluble fraction while the most
slowly migrating form is found predominantly in the insoluble frac-
tion that contains nuclei. Whether or not this CAST isoform is a nucle-
ar protein or is instead present in other insoluble compartments or
aggregates that are present in the “nuclear” fraction remains to be
clearly deﬁned. A correlation between the inhibitory efﬁciency of
CAST and its localization to the cytoplasm or within aggregates has
been reported in various cell lines [43,61]. Soluble, non-aggregated
CAST binds and inhibits calpain more efﬁciently. Since the expression
of Syk signiﬁcantly increases the amount of CAST present in the solu-
ble fraction, the same fraction in which calpain is found to reside,
more CAST can associate with calpain in lysates generated from
Syk-positive as compared to Syk-negative cells.
Despite the higher level of CAST, the level of intracellular calpain ac-
tivity in live, intact cells is elevated in those expressing Syk. This in-
creased activity correlates with increased basal levels of intracellular
calcium, the positive regulator of calpain that induces the dissociation
of calpain and CAST. It is likely that this elevated level of CAST is a con-
sequence of the increased calpain activity as CAST expression at the
transcriptional level has been correlated with the cellular requirements
for calpain inhibition [43]. The elevated level of calcium in the
Syk-expressing cells correlates, in turn, with a reduced expression of
Bcl-2. We ﬁnd that, in MCF7 cells expressing normal levels of endoge-
nous Syk, intracellular levels of Bcl-2 are low. In contrast, levels of
Bcl-2 protein are much higher in Syk-deﬁcient MCF7 cells, but are
again reduced when Syk (as Syk-EGFP) is expressed. Bcl-2 interacts di-
rectly with the regulatory domain of the IP3 receptor through its BH4
domain to inhibit calcium release from the ER [62] and elevating its
level through the expression of exogenous FLAG-Bcl-2 reduces the in-
tracellular concentration of calcium in MCF7 cells. Similarly,
MDA-MB-231 cells, which also have elevated levels of CAST, also have
low levels of Bcl-2 relative to those in MCF7-BD cells. The expression
of exogenous Bcl-2 in these cells also reduces the intracellular level of
calcium. Thus, differences in the cellular level of Bcl-2 provide a reason-
able explanation for the observed differences in calcium levels, which,
in turn, modulate calpain activity and the levels of CAST expression.
2163B. Fei et al. / Biochimica et Biophysica Acta 1833 (2013) 2153–2164While the proteolysis of both RelA and PTP1B by calpain is ob-
served most readily in cell lysates, it is certainly possible that both
are also subject to regulation by proteolysis within the cell. Since
calpain activity is higher in Syk-expressing cells, we monitored possi-
ble effects of calpain inhibitors on Syk-modulated signaling events.
Previously, both calpain and Syk have been implicated in the regula-
tion of pathways leading to the activation of NF-κB [12–14,63–65].
We found that the inhibition of calpain activity in intact cells through
the expression of CAST does modulate the transcriptional activity of
NF-κB induced by the treatment of cells with TNF-α. Syk enhances
TNF-α-induced NF-κB activation in MCF7 breast cancer cells and the
overexpression of CAST alone also has a positive effect on TNF-α-
induced NF-κB activation. The expression of both CAST and Syk to-
gether leads to an even larger increase in signaling.
An important role for Syk in epithelial cells is its participation in the
integrin signaling pathway. The ligation of cell surface integrin receptors
enhances tyrosine phosphorylation of cellular proteins, in part through
the activation of Syk [3,7,8,26,66,67]. PTP1B has been implicated as a
key negative regulator of integrin-induced signaling and is activated by
calpain cleavage and integrin ligation [35,36,49,60,68,69]. Interestingly,
in Syk-expressing cells, integrin-mediated tyrosine-phosphorylation is
enhanced by the inhibition of calpain by calpeptin. Thus, it is reasonable
to speculate that the increase in integrin-stimulated tyrosine phosphory-
lation in Syk-expressing cells by calpeptin is a result of downregulated
PTP1B activity. PTP1B also has been identiﬁed by mass spectrometry as
a substrate for Syk in Syk-transfectedMDA-MB-231 cells [70] andwe ob-
serve an interaction between the two proteins. More Syk was detected at
the cell edge in spreading cells that were treated with calpeptin, indicat-
ing an induced accumulation of the kinase at its sites of activation that
might lead to its prolonged activation. Indeed, it has been reported that
followingβ3-integrin ligation, calpain is activated and proteolyzes the cy-
toplasmic tail of the integrin receptor that provides important binding
sites for Syk [69]. Interestingly, a reduced expression of CAST is associated
with the early stages of metastatic behavior in breast cancer cells [71],
consistent with a role for calpain in the regulation of motility via the en-
hanced disassembly of focal adhesions [72–74]. This is interesting as the
expression of Syk both enhances the expression of CAST and inhibits the
motility of breast cancer cells and reduces their metastatic behavior
[3,75].
Taken together, results reported here demonstrated that Syk regulates
calpain activity in MCF7 cells by modulating the intracellular concentra-
tions of calcium and upregulating the expression of CAST. Inhibition of
calpain enhances signaling events that are regulated by Syk, including
TNF-α-induced activation of NF-κB, as well as integrin ligation-induced
tyrosine phosphorylation. The reciprocal regulation between Syk and
calpain-CAST proteolytic system provides novel insights into the tumor
suppressing and promoting functions of Syk in breast epithelial cells.
Acknowledgements
This work was supported by United States Public Health Services
grants CA115465 and CA037372 awarded by the National Cancer In-
stitute. S.Y. was supported by the National Cancer Institute Cancer
Prevention Internship Program R25 CA128770 (D. Teegarden).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.05.010.
References
[1] R.L. Geahlen, Syk and pTyr'd: signaling through the B cell antigen receptor,
Biochim. Biophys. Acta 1793 (2009) 1115–1127.
[2] A. Mócsai, J. Ruland, V.L.J. Tybulewicz, The SYK tyrosine kinase: a crucial player in
diverse biological functions, Nat. Rev. Immunol. 10 (2010) 387–402.[3] P.J. Coopman, M.T. Do, M. Barth, E.T. Bowden, A.J. Hayes, E. Basyuk, J.K. Blancato,
P.R. Vezza, S.W. McLeskey, P.H. Mangeat, S.C. Mueller, The Syk tyrosine kinase
suppresses malignant growth of human breast cancer cells, Nature 406 (2000)
742–747.
[4] S. Yanagi, R. Inatome, T. Takano, H. Yamamura, Syk expression and novel function
in a wide variety of tissues, Biochem. Biophys. Res. Commun. 288 (2001)
495–498.
[5] C. Hoeller, C. Thallinger, B. Pratscher, M.D. Bister, N. Schicher, R. Loewe, E.
Heere-Ress, F. Roka, V. Sexl, H. Pehamberger, The non-receptor-associated tyro-
sine kinase Syk is a regulator of metastatic behavior in human melanoma cells,
J. Invest. Derm. 124 (2005) 1293–1299.
[6] J. Gibbins, J. Asselin, R. Farndale, M. Barnes, C.L. Law, S.P. Watson, Tyrosine
phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets,
J. Biol. Chem. 271 (1996) 18095–18099.
[7] C.K. Miranti, L. Leng, P. Maschberger, J.S. Brugge, S.J. Shattil, Identiﬁcation of a
novel integrin signaling pathway involving the kinase Syk and the guanine nucle-
otide exchange factor Vav1, Curr. Biol. 8 (1998) 1289–1299.
[8] D.G. Woodside, A. Obergfell, L. Leng, J.L. Wilsbacher, C.K. Miranti, J.S. Brugge, S.J.
Shattil, M.H. Ginsberg, Activation of Syk protein tyrosine kinase through interac-
tion with integrin beta cytoplasmic domains, Curr. Biol. 11 (2001) 1799–1804.
[9] A. Mocsai, C.L. Abram, Z. Jakus, Y. Hu, L.L. Lanier, C.A. Lowell, Integrin signaling in
neutrophils and macrophages uses adaptors containing immunoreceptor
tyrosine-based activation motifs, Nat. Immunol. 7 (2006) 1326–1333.
[10] M. Turner, P.J. Mee, P.S. Costello, O. Williams, A.A. Price, L.P. Duddy, M.T. Furlong,
R.L. Geahlen, V.L.J. Tybulewicz, Perinatal lethality and blocked B-cell development
in mice lacking the tyrosine kinase Syk, Nature 378 (1995) 298–302.
[11] A.M. Cheng, B. Rowley, W. Pao, A. Hayday, J.B. Bolen, T. Pawson, Syk tyrosine
kinase required for mouse viability and B-cell development, Nature 378 (1995)
303–306.
[12] M. Ulanova, L. Puttagunta, M. Marcet-Palacios, M. Duszyk, U. Steinhoff, F. Duta,
M.K. Kim, Z.K. Indik, A.D. Schreiber, A.D. Befus, Syk tyrosine kinase participates
in beta1-integrin signaling and inﬂammatory responses in airway epithelial
cells, Am. J. Physiol. Lung Cell Mol. Physiol. 288 (2005) L497–L507.
[13] Y. Takada, B.B. Aggarwal, TNF activates Syk protein tyrosine kinase leading to
TNF-induced MAPK activation, NF-kappaB activation, and apoptosis, J. Immunol.
173 (2004) 1066–1077.
[14] Q. Zhou, R.L. Geahlen, The protein-tyrosine kinase Syk interacts with
TRAF-interacting protein TRIP in breast epithelial cells, Oncogene 28 (2009)
1348–1356.
[15] R.M. Young, I.R. Hardy, R.L. Clarke, N. Lundy, P. Pine, B.C. Turner, T.A. Potter, Y.
Refaeli, Mouse models of non-Hodgkin lymphoma reveal Syk as an important
therapeutic target, Blood 113 (2009) 2508–2516.
[16] C.K. Hahn, J.E. Berchuck, K.N. Ross, R.M. Kakoza, K. Clauser, A.C. Schinzel, L. Ross, I.
Galinsky, T.N. Davis, S.J. Silver, D.E. Root, R.M. Stone, D.J. DeAngelo, M. Carroll,
W.C. Hahn, S.A. Carr, T.R. Golub, A.L. Kung, K. Stegmaier, Proteomic and genetic
approaches identify Syk as an AML target, Cancer Cell 16 (2009) 281–294.
[17] M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholome, M. Burger, N. Chevalier, L.
Vallat, J. Timmer, J.G. Gribben, H. Jumaa, H. Veelken, C. Dierks, K. Zirlik, Spleen ty-
rosine kinase is overexpressed and represents a potential therapeutic target in
chronic lymphocytic leukemia, Cancer Res. 69 (2009) 5424–5432.
[18] A. Singh, P. Greninger, D. Rhodes, L. Koopman, S. Violette, N. Bardeesy, J.
Settleman, A gene expression signature associated with “K-Ras addiction” reveals
regulators of EMT and tumor cell survival, Cancer Cell 15 (2009) 489–500.
[19] A.D. Baudot, P.Y. Jeandel, X. Mouska, U. Maurer, S. Tartare-Deckert, S.D.
Raynaud, J.P. Cassuto, M. Ticchioni, M. Deckert, The tyrosine kinase Syk regu-
lates the survival of chronic lymphocytic leukemia B cells through PKCδ and
proteasome-dependent regulation of Mcl-1 expression, Oncogene 28 (2009)
3261–3273.
[20] J. Zhang, C.A. Benavente, J. McEvoy, J. Flores-Otero, L. Ding, X. Chen, A. Ulyanov, G.
Wu, M. Wilson, J. Wang, R. Brennan, M. Rusch, A.L. Manning, J. Ma, J. Easton, S.
Shurtleff, C. Mullighan, S. Pounds, S. Mukatira, P. Gupta, G. Neale, D. Zhao, C. Lu,
R.S. Fulton, L.L. Fulton, X. Hong, D.J. Dooling, K. Ochoa, C. Naeve, N.J. Dyson, E.R.
Mardis, A. Bahrami, D. Ellison, R.K. Wilson, J.R. Downing, M.A. Dyer, A novel reti-
noblastoma therapy from genomic and epigenetic analyses, Nature 481 (2012)
329–334.
[21] K. Minobe, M. Onda, A. Iida, F. Kasumi, G. Sakamoto, Y. Nakamura, M. Emi, Allelic
loss on chromosome 9q is associated with lymph node metastasis of primary
breast cancer, Jpn. J. Cancer Res. 89 (1998) 916–922.
[22] Y. Yuan, R. Mendez, A. Sahin, J.L. Dai, Hypermethylation leads to silencing of the
SYK gene in human breast cancer, Cancer Res. 61 (2001) 5558–5561.
[23] Y.M. Sung, X. Xu, J. Sun, D. Mueller, K. Sentissi, P. Johnson, E. Urbach, F.
Seillier-Moiseiwitsch, M.D. Johnson, S.C. Mueller, Tumor suppressor function of
Syk in human MCF10A in vitro and normal mouse mammary epithelium in
vivo, PLoS One 4 (2009) e7445.
[24] Z. Dyss, P. Montcourrier, B. Vidal, C. Anguille, F. Merezegue, A. Sahuquet, P.H.
Mangeat, P.J. Coopman, The Syk tyrosine kinase localizes to the centrosomes
and negatively affects mitotic progression, Cancer Res. 65 (2005) 10872–10880.
[25] L. Wang, E. Devarajan, J. He, S.P. Reddy, J.L. Dai, Transcription repressor activity of
spleen tyrosine kinase mediates breast tumor suppression, Cancer Res. 65 (2005)
10289–10297.
[26] X. Zhang, U. Shrikhande, B.M. Alicie, Q. Zhou, R.L. Geahlen, Role of the protein ty-
rosine kinase Syk in regulating cell–cell adhesion and motility in breast cancer
cells, Mol. Cancer Res. 7 (2009) 634–644.
[27] W.J. Lee, H. Ma, E. Takano, H.Q. Yang, M. Hatanaka, M. Maki, Molecular diversity in
amino-terminal domains of human calpastatin by exon skipping, J. Biol. Chem.
267 (1992) 8437–8442.
2164 B. Fei et al. / Biochimica et Biophysica Acta 1833 (2013) 2153–2164[28] T. Parr, P.L. Sensky, R.G. Bardsley, P.J. Buttery, Calpastatin expression in porcine
cardiac and skeletal muscle and partial gene structure, Arch. Biochem. Biophys.
395 (2001) 1–13.
[29] M. Cong, V.F. Thompson, D.E. Goll, P.B. Antin, The bovine calpastatin gene
promoter and a new N-terminal region of the protein are targets for cAMP-
dependent protein kinase activity, J. Biol. Chem. 273 (1998) 660–666.
[30] J. Takano, M. Watanabe, K. Hitomi, M. Maki, Four types of calpastatin isoforms
with distinct amino-terminal sequences are speciﬁed by alternative ﬁrst exons
and differentially expressed in mouse tissues, J. Biochem. 128 (2000) 83–92.
[31] J. Rios-Doria, K.C. Day, R. Kuefer, M.G. Rashid, A.M. Chinnaiyan, M.A. Rubin, M.L.
Day, The role of calpain in the proteolytic cleavage of E-cadherin in prostate
and mammary epithelial cells, J. Biol. Chem. 278 (2003) 1372–1379.
[32] L. Löfvenberg, L. Backman, Calpain-induced proteolysis of beta-spectrins, FEBS
Lett. 443 (1999) 89–92.
[33] P. Cooray, Y. Yuan, S.M. Schoenwaelder, C.A. Mitchell, H.H. Salem, S.P. Jackson,
Focal adhesion kinase (pp125FAK) cleavage and regulation by calpain, Biochem.
J. 318 (1996) 41–47.
[34] A. Kishimoto, K.Mikawa, K. Hashimoto, I. Yasuda, S. Tanaka,M. Tominaga, T. Kuroda,
Y. Nishizuka, Limited proteolysis of protein kinase C subspecies by calcium-
dependent neutral protease (calpain), J. Biol. Chem. 264 (1989) 4088–4092.
[35] J.V. Frangioni, A. Oda, M. Smith, E.W. Salzman, B.G. Neel, Calpain-catalyzed cleav-
age and subcellular relocation of protein phosphotyrosine phosphatase 1B
(PTP-1B) in human platelets, EMBO J. 12 (1993) 4843–4856.
[36] S.M. Kuchay, N. Kim, E.A. Grunz, W.P. Fay, A.H. Chishti, Double knockouts reveal
that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in
platelets, Mol. Cell. Biol. 27 (2007) 6038–6052.
[37] S.M. Azarian, A.J. King, M.A. Hallett, D.S. Williams, Selective proteolysis of arrestin
by calpain, J. Biol. Chem. 270 (1995) 24375–24384.
[38] S. Hirai, H. Kawasaki, M. Yaniv, K. Suzuki, Degradation of transcription factors,
c-Jun and c-Fos, by calpain, FEBS Lett. 287 (1991) 57–61.
[39] M. Pariat, C. Salvat, M. Bebien, F. Brockly, E. Altieri, S. Carillo, I. Jariel-Encontre, M.
Piechaczyk, The sensitivity of c-Jun and c-Fos proteins to calpains depends on
conformational determinants of the monomers and not on formation of dimmers,
Biochem. J. 345 (2000) 129–138.
[40] M.H. Kubbutat, K.H. Vousden, Proteolytic cleavage of human p53 by calpain: a po-
tential regulator of protein stability, Mol. Cell. Biol. 17 (1997) 460–468.
[41] H. Shiraha, A. Glading, J. Chou, Z. Jia, A. Wells, Activation of m-calpain (calpain II)
by epidermal growth factor is limited by protein kinase A phosphorylation of
m-calpain, Mol. Cell. Biol. 22 (2002) 2716–2727.
[42] A. Glading, R.J. Bodnar, I.J. Reynolds, H. Shiraha, L. Satish, D.A. Potter, H.C. Blair, A.
Wells, Epidermal growth factor activates m-calpain (calpain II), at least in part, by
extracellular signal-regulated kinase-mediated phosphorylation, Mol. Cell. Biol.
24 (2004) 2499–2512.
[43] M. Averna, R. De Tullio, P. Capini, F. Salamino, S. Pontremoli, E. Melloni, Changes
in calpastatin localization and expression during calpain activation: a new mech-
anism for the regulation of intracellular Ca(2+)-dependent proteolysis, Cell. Mol.
Life Sci. 60 (2003) 2669–2678.
[44] J.G. Tidball, M.J. Spencer, Calpains and muscular dystrophies, Int. J. Biochem. Cell
Biol. 32 (2000) 1–5.
[45] S. Sandmann, M. Yu, T. Unger, Transcriptional and translational regulation of
calpain in the rat heart after myocardial infarction-effects of AT(1) and AT(2) re-
ceptor antagonists and ACE inhibitor, Br. J. Pharmacol. 132 (2001) 767–777.
[46] T. Tsuji, S. Shimohama, J. Kimura, K. Shimizu, m-Calpain (calcium-activated neu-
tral proteinase) in Alzheimer's disease brains, Neurosci. Lett. 248 (1998) 109–112.
[47] A. Mamoune, J.-H. Luo, D.A. Lauffenburger, A. Wells, Calpain-2 as a target for lim-
iting prostate cancer invasion, Cancer Res. 63 (2003) 4632–4640.
[48] V. Gonscherowski, B.F. Becker, L. Moroder, E. Motrescu, S. Gil-Parrado, T. Gloe, M.
Keller, S. Zahler, Calpains: a physiological regulator of the endothelial barrier?
Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H2035–H2042.
[49] L.A. Maile, A.W. Aday, W.H. Busby, R. Sanghani, U. Veluvolu, D.R. Clemmons, Mod-
ulation of integrin antagonist signaling by ligand binding of the heparin-binding
domain of vitronectin to the alphaVbeta3 integrin, J. Cell. Biochem. 105 (2008)
437–446.
[50] H. Ma, T.M. Yankee, J. Hu, D.J. Asai, M.L. Harrison, R.L. Geahlen, Visualization of
Syk-antigen receptor interactions using green ﬂuorescent protein: differential
roles for Syk and Lyn in the regulation of receptor capping and internalization,
J. Immunol. 166 (2001) 1507–1516.
[51] L. Tian, S.A. Hires, T. Mao, D. Huber, M.E. Chiappe, S.H. Chalasani, L. Petreanu, J.
Akerboom, S.A. McKinney, E.R. Schreiter, C.I. Bargmann, V. Jayaraman, K.
Svoboda, L.L. Looger, Imaging neural activity in worms, ﬂies and mice with im-
proved GCaMP calcium indicators, Nat. Methods 6 (2009) 875–881.
[52] F. Pellegatta, A.A. Bertelli, B. Staels, C. Duhem, A. Fulgenzi, M.E. Ferrero, Different
short- and long-term effects of resveratrol on nuclear factor-kappaB phosphory-
lation and nuclear appearance in human endothelial cells, Am. J. Clin. Nutr. 77
(2003) 1220–1228.[53] K.M. Bijli, F. Fazal, M. Minhajuddin, A. Rahman, Activation of Syk by protein kinase
C-delta regulates thrombin-induced intercellular adhesion molecule-1 expression
in endothelial cells via tyrosine phosphorylation of RelA/p65, J. Biol. Chem. 283
(2008) 14674–14684.
[54] R.P. Guttmann, J.S. Elce, P.D. Bell, J.C. Isbell, G.V. Johnson, Oxidation inhibits substrate
proteolysis by calpain I but not autolysis, J. Biol. Chem. 272 (1997) 2005–2012.
[55] R.P. Guttmann, G.V. Johnson, Oxidative stress inhibits calpain activity in situ,
J. Biol. Chem. 273 (1998) 13331–13338.
[56] R. Lametsch, S. Lonergan, E. Huff-Lonergan, Disulﬁde bondwithin mu-calpain active
site inhibits activity and autolysis, Biochim. Biophys. Acta 1784 (2008) 1215–1221.
[57] S.-H. Jang, S.A. Hwang, M. Kim, S.-H. Yun, M.-S. Kim, S.S. Karnik, C. Lee, A protein
tyrosine phosphatase inhibitor, pervanadate, inhibits angiotensin II-induced
β-arrestin cleavage, Mol. Cells 28 (2009) 25–30.
[58] R. Chen, I. Valencia, F. Zhong, K.S. McColl, H.L. Roderick, M.D. Bootman, M.J.
Berridge, S.J. Conway, A.B. Holmes, G.A. Mignery, P. Velez, C.W. Distelhorst,
Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate
calcium release from the ER, J. Cell Biol. 166 (2004) 193–203.
[59] F. Zhong, M.W. Harr, G. Bultynck, G. Monaco, J.B. Parys, H. De Smedt, Y.-P. Rong, J.K.
Molitoris, M. Lam, C. Ryder, S. Matsuyama, C.W. Distelhorst, Induction of
Ca2+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated
disruption of Bcl-2–IP3 receptor interaction, Blood 117 (2011) 2924–2934.
[60] C.L. Cortesio, K.T. Chan, B.J. Perrin, N.O. Burton, S. Zhang, Z.Y. Zhang, A.
Huttenlocher, Calpain 2 and PTP1B function in a novel pathway with Src to regu-
late invadopodia dynamics and breast cancer cell invasion, J. Cell Biol. 180 (2008)
957–971.
[61] M. Averna, R. de Tullio, M. Passalacqua, F. Slaamino, S. Pontremoli, E. Melloni,
Changes in intracellular calpastatin localization are mediated by reversible phos-
phorylation, Biochem. J. 354 (2001) 25–30.
[62] Y.-P. Rong, G. Bultynck, A.S. Aromolaran, F. Zhong, J.B. Parys, H. De Smedt, G.A.
Mignery, H.L. Roderick, M.D. Bootman, C.W. Distelhorst, The BH4 domain of
Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and
coupling domain of the IP3 receptor, Proc. Natl. Acad. Sci. U.S.A. 106 (2009)
14397–14402.
[63] K. Schaecher, J.M. Goust, N.L. Banik, The effects of calpain inhibition on IkB alpha
degradation after activation of PBMCs: identiﬁcation of the calpain cleavage sites,
Neurochem. Res. 29 (2004) 1443–1451.
[64] F. Chen, L.M. Demers, V. Vallyathan, Y. Lu, V. Castranova, X. Shi, Impairment of
NF-kappaB activation and modulation of gene expression by calpastatin, Am. J.
Physiol. Cell Physiol. 279 (2000) C709–C716.
[65] Y. Han, S. Weinman, I. Boldogh, R.K. Walker, A.R. Brasier, Tumor necrosis factor-
alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A
mechanism parallel to the ubiquitin–proteasome pathway for nuclear factor-
kappab activation, J. Biol. Chem. 274 (1999) 787–794.
[66] T.H. Lin, C. Rosales, K. Mondal, J.B. Bolen, S. Haskill, R.L. Juliano, Integrin-mediated
tyrosine phosphorylation and cytokine message induction in monocytic cells. A
possible signaling role for the Syk tyrosine kinase, J. Biol. Chem. 270 (1995)
16189–16197.
[67] A. Obergfell, K. Eto, A. Mocsai, C. Buensuceso, S.L. Moores, J.S. Brugge, C.A. Lowell,
S.J. Shattil, Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb
[beta]3 initiate integrin signaling to the cytoskeleton, J. Cell. Biol. 157 (2002)
265–275.
[68] F. Liu, M.A. Sells, J. Chernoff, Protein tyrosine phosphatase 1B negatively regulates
integrin signaling, Curr. Biol. 8 (1998) 173–176.
[69] X. Du, T.C. Saido, S. Tsubuki, F.E. Indig, M.J. Williams, M.H. Ginsberg, Calpain cleav-
age of the cytoplasmic domain of the integrin beta 3 subunit, J. Biol. Chem. 270
(1995) 26146–26151.
[70] A.B. Iliuk, V.A. Martin, B.M. Alicie, R.L. Geahlen, W.A. Tao, In-depth analyses of
kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized
soluble nanopolymers, Mol. Cell. Proteomics 9 (2010) 2162–2172.
[71] S.J. Storr, R.A.A. Mohammeda, C.M. Woolston, A.R. Green, T. Parr, I. Spiteri, C. Caldas,
G.R. Ball, I.O. Ellis, S.G. Martin, Calpastatin is associated with lymphovascular inva-
sion in breast cancer, Breast 20 (2011) 413–418.
[72] M.C. Beckerle, K. Burridge, G.N. DeMartino, D.E. Croall, Colocalization of calcium-
dependent protease II and one of its substrates at sites of cell adhesion, Cell 51
(1987) 569–577.
[73] B.D. Cuevas, A.N. Abell, J.A. Witowsky, T. Yujiri, N.L. Johnson, K. Kesavan, M. Ware,
P.L. Jones, S.A. Weed, R.L. DeBiasi, Y. Oka, K.L. Tyler, G.L. Johnson, MEKK1 regulates
calpain-dependent proteolysis of focal adhesion proteins for rear-end detach-
ment of migrating ﬁbroblasts, EMBO J. 22 (2003) 3346–3355.
[74] A. Huttenlocher, S.P. Palecek, Q. Lu, W. Zhang, R.L. Mellgren, D.A. Lauffenburger,
M.H. Ginsberg, A.F. Horwitz, Regulation of cell migration by the calcium-
dependent protease calpain, J. Biol. Chem. 272 (1997) 32719–32722.
[75] Y. Yuan, H. Liu, A. Sahin, J.L. Dai, Reactivation of SYK expression by inhibition of
DNA methylation suppresses breast cancer cell invasiveness, Int. J. Cancer 113
(2005) 654–659.
